Klothos Neurosciences Inc. (KLTO) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Klothos Neurosciences Inc. (KLTO:NASDAQ), powered by AI.

Current Price
$0.52
P/E Ratio
-1.6
Market Cap
10M
Sector
Healthcare
What is the Klothos Neurosciences Inc. stock price forecast?

Klothos Neurosciences Inc. is currently trading at $0.52. View real-time AI analysis on Alpha Lenz.

What is Klothos Neurosciences Inc. insider trading activity?

View the latest insider trading data for Klothos Neurosciences Inc. on Alpha Lenz.

What is Klothos Neurosciences Inc.'s P/E ratio?

Klothos Neurosciences Inc.'s P/E ratio is -1.6.

Klothos Neurosciences Inc.

NASDAQ · KLTO
$0.52+0.00(+0.83%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Klothos Neurosciences Inc.'s future dividend policy...
Alpha Chat Insight

Klothos Neurosciences Inc. trades at a P/E of -1.6 (undervalued) with modest ROE of -518.9%.

Ask for details

Company Overview

Klothos Neurosciences Inc. is a cutting-edge biotechnology company devoted to the development of innovative therapies for neurological disorders. This organization leverages advanced scientific research and cutting-edge technology to address complex diseases impacting the brain and nervous system, such as Alzheimer's, Parkinson's, and other neurodegenerative conditions. By focusing on breakthrough innovations and targeted treatment approaches, Klothos Neurosciences aims to improve patient outcomes and quality of life significantly. Anchored in a robust pipeline of drug candidates and a commitment to scientific excellence, Klothos collaborates with key stakeholders, including research institutions and healthcare providers, to drive progress in neuroscience. As a participant in the biotechnology sector, the company contributes significantly to the broader healthcare and life sciences industries, offering potential solutions to unmet medical needs. With its headquarters poised at the intersection of technology and medicine, Klothos Neurosciences remains a pivotal player in the relentless pursuit to conquer neurological illnesses through scientifically backed therapies.

CEODr. Joseph Sinkule Pharm.D.
SectorHealthcare
IndustryBiotechnology
Employees3

Company Statistics

FY 2024

Profile

$10.09MMarket Cap
$0.00Revenue
0.00Shares Out
3Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-1.64P/E
8.51P/B
N/AEV/Sales
-1.78EV/EBITDA
-3.29P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-250.28%ROA
-518.87%ROE
-235.77%ROIC

Financial Health

$63.74KCash & Cash Equivalents
$1.21MNet Debt
107.31%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Klothos Neurosciences Inc. (ticker: KLTO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 3 employees. Market cap is $10M.

The current price is $0.524 with a P/E ratio of -1.64x and P/B of 8.51x.

ROE is -518.87%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Klothos Neurosciences Inc. (KLTO) Stock Forecast 2026 $0.52 — Price, Financials & Analyst Targets | Alpha Lenz